aod9604 and semaglutide AOD-9604 (10mg vials) Chevy Chase AOD 9604 Anti-Obesity

The increased NAD+ availability supports more efficient ATP (cellular energy) production, potentially translating to better endurance, improved workout performance, and faster recovery between training sessions

Rapid weight loss from any method can temporarily increase hair shedding

Administered intramuscularly or intravenously

Nausea (most common, typically dose-dependent and transient) Diarrhea or constipation during dose escalation Vomiting, especially when starting or increasing dose Reduced appetite and early satiety Injection site reactions (redness, bruising) Fatigue, particularly in early weeks Rare: Pancreatitis discontinue immediately with severe abdominal pain Rare: Thyroid C-cell effects (contraindicated with MEN2 or thyroid cancer history) AOD-9604 is a modified C-terminal fragment (residues 176191, Tyr-hGH177-191) of human growth hormone, studied for lipolytic and anti-obesity properties

Perspective The primary analytic perspective was that of the Ministry of Health and Long-Term Care

Special checks are made on observations that are more than two or three SDs from the mean